Palvella Therapeutics (PVLA) Income towards Parent Company: 2013-2024
Historic Income towards Parent Company for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to -$4.0 million.
- Palvella Therapeutics' Income towards Parent Company fell 128.55% to -$4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 74.03%. This contributed to the annual value of -$17.4 million for FY2024, which is 193.27% down from last year.
- As of Q4 2024, Palvella Therapeutics' Income towards Parent Company stood at -$4.0 million, which was up 41.68% from -$6.8 million recorded in Q3 2024.
- Palvella Therapeutics' Income towards Parent Company's 5-year high stood at $13.8 million during Q4 2023, with a 5-year trough of -$19.0 million in Q3 2021.
- For the 3-year period, Palvella Therapeutics' Income towards Parent Company averaged around -$5.9 million, with its median value being -$7.1 million (2022).
- In the last 5 years, Palvella Therapeutics' Income towards Parent Company crashed by 1,508.69% in 2020 and then surged by 223.93% in 2023.
- Over the past 5 years, Palvella Therapeutics' Income towards Parent Company (Quarterly) stood at -$12.4 million in 2020, then grew by 11.27% to -$11.0 million in 2021, then fell by 1.48% to -$11.2 million in 2022, then soared by 223.93% to $13.8 million in 2023, then slumped by 128.55% to -$4.0 million in 2024.
- Its last three reported values are -$4.0 million in Q4 2024, -$6.8 million for Q3 2024, and -$4.2 million during Q2 2024.